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Abstract
Purpose We evaluated the performance of the placental
alpha-microglobulin-1 immunoassay (AmniSure, AT) in
cervicovaginal secretions in patients with uncertain rupture
of membranes (ROM) and investigated the influence of the
examiners experience.
Methods This prospective cohort study was performed in
pregnant women (17–42 weeks of gestation) with signs of
possible ROM. Evaluation included clinical assessment,
examination for cervical leakage, Nitrazine test and mea-
surement of the amniotic fluid index by ultrasound and AT.
ROM occurrence was based on review of the medical
records after delivery.
Results 199 women were included. AT had a sensitivity of
94.4%; specificity of 98.6%; positive predictive value,
96.2%; negative predictive value, 98.0%. Clinical assessment
showed a sensitivity of 72.2%; specificity of 97.8%; positive
predictive value, 92.9%; negative predictive value, 90.6%.
AT was more sensitive for diagnosing ROM (p = 0.00596)
compared to clinical assessment, independent of the
examiners experience. Furthermore, the sole use of AT
reduced costs by 58.4% compared to clinical assessment.
Conclusions AT was more sensitive compared to clinical
assessment, independent of the examiners experience and
gestational age. Our data extend its use in patients with
uncertain ROM. Moreover, AT seems to be a cost-effective
approach in the assessment of these patients.
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Introduction
Preterm premature rupture of membranes (PPROM) before
37 weeks of gestation has an incidence of 2–3%, leads to
30–40% of preterm deliveries and is associated with an
increased risk of perinatal morbidity and mortality [1–3].
Accurate diagnosis of PPROM would allow for gestational
age-specific obstetric treatment but conversely, false-positive
diagnosis may lead to unnecessary obstetric interventions
such as hospitalisation or induction of labor.
The diagnosis of rupture of membranes (ROM) is
largely a clinical diagnosis and is based on visual
assessment when obvious leakage of amniotic fluid (AF)
has occurred, but is more difficult when the leakage is
subtle and intermittent, which occurs in up to 20% of all
women with ROM [4]. The current conventional clinical
assessment includes taking an accurate history, demon-
stration of visible AF in the vagina with a speculum
examination, microscopic examination of the fluid for
ferning of dried cervicovaginal discharge and the Nitr-
azine test. Unfortunately, Nitrazine testing of vaginal pH
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has an appreciable false-positive rate due to blood con-
tamination, semen or bacterial vaginosis [5, 6]. The fern
test also shows a considerable rate of false-positivity [7].
Both tests are time dependent and become progressively
less accurate when 1 h has elapsed after ROM. Preg-
nancies complicated by ROM usually show a decreased
amniotic fluid index (AFI) by transabdominal ultrasound,
and ultrasound is therefore recommended as an additional
diagnostic tool [8, 9]
The AmniSure immunoassay (AT) is highly sensitive
for placental Alpha-Microglobulin-1, (PAMG-1), a 34 kDa
fetal glycoprotein, which was first isolated in 1975 from
amniotic fluid by D. Petrunin [10]. PAMG-1 is present
throughout all three trimesters of pregnancy in blood,
amniotic fluid and cervicovaginal discharge of pregnant
women. The concentration in the amniotic fluid
(2,000–25,000 ng/ml), however, is 1,000- to 10,000-fold
higher than that found in the background cervicovaginal
discharge when the fetal membranes are intact
(0.05–0.2 ng/ml) (AmniSure test, package insert). Previ-
ous studies in patients with clear signs of PPROM reported
a higher sensitivity and specificity with this assay com-
pared to conventional clinical assessment which did not
include AFI measurements [11, 12].
The aim of this prospective cohort study was to evaluate
the reliability of the AT as a bedside test for uncertain
ROM in a European collective compared with conventional
clinical assessment including pooling of AF in the vagina,
Nitrazine test evaluation and sonographic measurement of
AFI, to evaluate the influence of examiner experience and
to assess the cost-effectiveness of AT.
Materials and methods
In this prospective observational study, pregnant women in
two Swiss centres [Department of Obstetrics and Gynae-
cology, University of Basel (approx. 2,000 deliveries/year)
and Kantonsspital Liestal (approx. 600 deliveries/year)] in
Switzerland were asked to participate with written
informed consent. Approval for this study was obtained
from the institutional review board of the University of
Basel, Switzerland.
The inclusion criteria consisted of women with singleton
pregnancies in cephalic position and uncertain signs or
symptoms of ROM (patient complaint of leakage of fluid
without complete, obvious rupture of membranes) in the
second or third trimester. Patients with clear signs of ROM
(large gush of clear vaginal fluid or a steady trickle) were
excluded from the study. Also patients with active bleeding
or vaginal examination in the last 12 h, severe pregnancy
complications like preeclampsia, fetal malformation or
death were excluded.
On admission of the patient, a conventional clinical
assessment was performed, including the medical history,
followed by a physical examination including a sterile
speculum examination (without the use of antiseptic solu-
tion or lubricant) and Nitrazine test. In addition AT was
performed according to the manufacturer’s instructions
(Pro Concepta AG, Zug, Switzerland). A sterile Dacron
swab was placed in the posterior fornix of the vagina. After
a period of 1 min, the swab was removed and agitated in a
vial containing solvent for 1 min. The AT test strip was
then placed in the solvent and the sample in the vial was
allowed to migrate through the membrane strip by capillary
action; the test result was available within 5 min.
Following this, all patients underwent a measurement of
the AFI by transabdominal ultrasound according to Phelan
et al. [13], using a 5-MHz transabdominal probe (Hitachi
EUB-6000 plus, Hitachi Medical Systems, Germany and
Toshiba Powervision 6000 ultrasound machine, Toshiba
Medical Systems, Switzerland).
The diagnosis of ROM was made using the conventional
clinical assessment if two of the following three criteria
were positive: (1) visual leaking or pooling of AF from the
cervix on the speculum examination, (2) positive Nitrazine
test or (3) AFI \5 cm in the ultrasound examination. The
experience of each examiner was recorded according to the
years of training of the respective physician.
During the clinical assessments, physicians were not
aware of the AT result, but were informed after the
examination. In 16 cases with positive AT and a negative
clinical assessment, the AT result was taken into account
and the pregnant women were hospitalised and closely
followed. Finally, 14 turned out to be correctly positive and
2 were false positive by AT.
Due to our limited experience with AT, the subsequent
obstetrical management was based solely on the clinical
assessment.
ROM was diagnosed definitively on review of the
medical records when there was documented evidence of
intact or ruptured membranes with consecutive loss of fluid
during delivery. The sensitivity, specificity and positive/
negative predictive value of the AT in diagnosing ROM
was compared to the clinical assessment. The costs of both
diagnostic approaches were calculated by using the ascer-
tained costs of each examination based on the national
reimbursement setting (TARMED, deduced from ‘‘tarif
me´dical’’, http://www.tarmedsuisse.ch).
Statistical analysis
A power calculation was initially performed to compare
sensitivity and specificity: with a sample size of 199
patients, there is a power of [80 to detect a minimal sig-
nificant difference of 6% between the shift for AT positive
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to clinical negative patients, compared to a shift from AT
negative to clinical positive patients (McNemar test,
alpha = 5%, two-sided). Sensitivities, specificities, nega-
tive predictive values and positive predictive values were
estimated with a 95% confidence interval using the corre-
sponding binomial distribution. To compare sensitivities
and specificities, McNemar’s Chi-square test was per-
formed. Logistic regression was employed to detect influ-
ences on performance of AT and clinical assessment. A
p value \0.05 was considered as significant (two-sided
tests). All analyses were done using R version 2.7.1 (R: A
language and environment for Statistical Computing).
Results
202 pregnant women were enrolled and of these, three had to
be excluded retrospectively due to incomplete medical
records. The median age in the collective of 199 women was
28.8 years (interquartile range, IQR 24.5–33.5 years); the
median gestational age was 38 weeks [IQR 34–40 weeks,
range 17–42 weeks (Fig. 1)]. 55% (109 of 199) were at term
(37 ? 0 or later) and 45% (90 of 199) were preterm.
AT was positive in 53/199 (26.6%) and clinical
assessment led to the diagnosis of ROM in 42/199 (21.1%)
patients. After review of the medical records, ROM was
confirmed in 54/199 (27.1%) patients.
There were three false-negative cases tested by AT and
15 after clinical assessment. One of these cases was false
negative in both diagnostic methods, while the remaining
(two for AT and 14 for clinical assessment) were discor-
dantly false negative in both diagnostic approaches. There
were two false-positive cases for AT and three for clinical
assessment in independent patients (Fig. 2).
In women with a positive AT and a false-negative clinical
assessment (n = 14), the median (IQR) gestational age was
39 weeks (38–40). The gestational age in those cases was
very similar to the remaining cases of positive AT and
correctly positive clinical assessment [n = 37, gestational
age: 40 weeks (35.5–40.5), p = 0.5053]. In the mentioned
14 cases, clinical assessment was positive within the next
12–24 h and ROM confirmed during delivery.
Specificity [98.6% (CI 0.95–1.00)], positive predictive
value [96.2% (CI 0.87–1.00)] and negative predictive value
[98.0% (CI 0.94–1.00)] of AT did not differ from clinical
assessment [specificity 97.9% (CI 0.94–1.00), positive
predictive value 92.9% (CI 0.81–0.99), negative predictive
value 90.5% (CI 0.85–0.99)]. At the same specificity
(p = 1.0), AT was more sensitive [94.4% (CI 0.85–0.99)]
in diagnosing ROM than clinical evaluation [72.2%
(CI 0.58–0.84), p = 0.00596].
Gestational age had no influence on sensitivity and
specificity of AT (p = 0.61 and 0.29) or the clinical
assessment (p = 0.61 and 0.66). Clinical assessment relies
on the ability to visualize pooling of AF during the spec-
ulum examination. Nevertheless, experience of the treating
physician had no influence on the accuracy of the clinical
diagnosis. Sensitivity and specificity were the same in
experienced (three or more years of working experience)
versus less experienced treating physicians (sensitivity,
p = 0.50 and specificity, p = 1.0).
According to local calculations (based on TARMED),
we evaluated the costs for each individual diagnostic test.
Compared to the clinical evaluation (total costs 122.5
Euro) a cost reduction of 58.8% could be achieved by using
only AT (total costs 50.5 Euro) (Table 1).
Discussion
The diagnosis of ROM remains difficult when there is no
clear leakage of fluid. ROM is associated with a high
20
30
40
G
es
ta
tio
na
l a
ge
 (w
ee
ks
)
N=199
Fig. 1 Gestational age of the study collective (Median and inter-
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Fig. 2 Test results ROM rupture of membranes, AT AmniSure
immunoassay, clinic clinical assessment. Displayed are the propor-
tions of positive/negative AT or clinical assessment in patients with
confirmed ROM and in patients without ROM
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perinatal mortality and maternal morbidity [1–3]; there-
fore, a specific non-invasive test or biochemical marker
would be highly helpful to diagnose uncertain rupture of
membranes. These limitations of conventional methods
stimulated the search for non-invasive tests based on the
detection of biochemical markers in cervicovaginal dis-
charge such as alpha-fetoprotein [14, 15], vaginal prolactin
[16], fetal fibronectin [17, 18], beta-subunit of human
chorionic gonadotropin (b-hCG) [19], creatinine [20], urea
[21], lactate [22], and insulin-like growth factor binding
protein-1 (IGFBP-1) [23–27]. However, none of them
turned out to be the optimal marker for ROM, as they are
gestational-age dependent, such as fetal fibronectin, or
require a speculum examination, as with IGFBP-1. A
recent study by Tagore et al. [28] demonstrated that AT
performed equal or even superior in detecting ROM than
the IGFBP-1 rapid strip test (Actim PROM) with a sen-
sitivity of 92.7 versus 87.5% and a specificity of 100 versus
94.4%.
Physician qualification has an impact on the traditional
clinical assessment with speculum examination, visualiza-
tion of cervical leakage, performance and evaluation of the
Nitrazine test or ferning, and the measurement of the AFI
by transabdominal ultrasound. In contrast, our study dem-
onstrated that the AT is not training-dependent and is more
sensitive at same specificity compared to clinical assess-
ment. We included patients with gestational ages ranging
from 17 to 42 weeks and demonstrated that the duration of
pregnancy had no influence on sensitivity and specificity of
AT.
Our data confirm and extend the excellent sensitivity
and specificity of AT reported previously [11, 12, 23]. Lee
et al. and Cousin et al. [11, 12] both found AT to be highly
sensitive (98.7 and 98.9% compared to 94.4% in our study)
and specific (87.5 and 100% compared to 98.6% in our
study). However, both studies used pooling, Nitrazine test
and ferning for clinical evaluation of ROM which is rarely
used in Europe. In clear contrast to the previous studies, all
of our participants presented with uncertain ROM, and
clinical assessment included more comprehensive diag-
nostic measures such as ultrasound.
At the current time further reduction of costs does not
seem feasible, as ultrasound is recommended in interna-
tional and national guidelines in cases with ROM; never-
theless, the savings could be 58.8% using AT alone instead
of the traditional approach.
In conclusion, AT is a simple, reliable, highly sensitive
and cost-effective test with superior performance compared
to clinical assessment in the diagnosis of ROM in the
second and third trimesters. Early diagnosis clearly helps to
avoid long- and short-term sequelae of ROM and mini-
mizes serious adverse outcomes, such as chorioamnionitis
and neonatal sepsis. Further studies should evaluate the
performance of AT in an outpatient midwifery-based set-
ting or in countries where technical equipment is less
available.
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